A de novo, intragenic frameshift variant titrates NaV1.6 through a Goldilocks window in which intermediate reduction rescues Gain-of-function epilepsy, whereas insufficient or excessive reduction remains lethal, validating Scn8a-lowering and its therapeutic dose window.
Erfan Bahramnejad, Victor J. Hiller, Michael F. Hammer· bioRxiv· 0 citations
Clinical heterogeneity in SCN8A-related disorders is patterned along molecular dimensions that go beyond the specific genetic alteration, to include position in the linear channel topology, proximity to post-translational modification (PTM) and structural sites, and predicted effects on mRNA splicing.
Joshua B. Hack, J. Watkins, Michael F. Hammer· bioRxiv· 0 citations
The findings show that the two clinical directions of SCN8A disease have distinct tissue-level correlates and call for opposite therapeutic logic, channel or injury-cascade suppression for GoF and restoration of channel output for LoF, and identify a conserved, seizure-driven injury core as a tractable cross-disease ta...
Michael F. Hammer, Erfan Bahramnejad· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.